التفاصيل البيبلوغرافية
| العنوان: |
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline -inactivating mutations. |
| المؤلفون: |
Rodón, Jordi, Funchain, Pauline, Laetsch, Theodore W, Arkenau, Hendrik-Tobias, Hervieu, Alice, Singer, Christian F, Murciano-Goroff, Yonina R, Chawla, Sant P, Anthony, Kristin, Yamamiya, Ikuo, Liu, Mei, Halim, Abdel-Baset, Benhadji, Karim A, Takahashi, Osamu, Delaloge, Suzette |
| المصدر: |
Future Oncology; Sep2022, Vol. 18 Issue 30, p3377-3387, 11p |
| مستخلص: |
PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the PTEN gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an effective approach in cancer patients having germline PTEN mutations. The mechanism of action, safety and dosing regimen for the novel allosteric AKT inhibitor TAS-117 have been explored in a phase I study in Japan in which activity was observed against certain tumor types. Here we describe the study protocol of an international, two-part phase II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
